Literature DB >> 19485807

Postoperative Crohn's disease: prevention and treatment.

Sandra El-Hachem1, Miguel Regueiro.   

Abstract

Crohn's disease is a chronic, relapsing-remitting inflammatory disease of the intestinal tract that commonly requires surgical treatment. Unfortunately, the majority of patients will ultimately develop postoperative disease recurrence and require subsequent surgery. A number of medications have been researched for the maintenance of postoperative remission. Of these, few have demonstrated consistent efficacy. A recently published randomized, controlled trial indicated that infliximab is effective in the maintenance of postoperative remission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19485807     DOI: 10.1586/egh.09.21

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  4 in total

1.  Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.

Authors:  Miguel Regueiro; Sandra El-Hachem; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Andrew Watson; Jason Swoger; Marc Schwartz; Arthur Barrie; Marilyn Pesci; David Binion
Journal:  Dig Dis Sci       Date:  2011-06-17       Impact factor: 3.199

2.  Risk Stratification for Prevention of Recurrence of Postoperative Crohn's Disease.

Authors:  Shirley Cohen-Mekelburg; Yecheskel Schneider; Stephanie Gold; Ellen Scherl; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

Review 3.  Biologic therapy and surgery for crohn disease.

Authors:  E Carter Paulson
Journal:  Clin Colon Rectal Surg       Date:  2013-06

4.  What is the Important Issue to Prevent the Postoperative Crohn's Disease?

Authors:  You Sun Kim
Journal:  Intest Res       Date:  2014-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.